Cizolirtine citrate
| Code | Size | Price |
|---|
| TAR-T27025-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27025-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Cizolirtine is a calcitonin gene-related peptide antagonist. Cizolirtine may be useful for alleviating some neuropathic somatosensory disorders, in particular cold allodynia, with a reduced risk of undesirable side effects. Cizolirtine inhibits the spinal release of substance P and CGRP in rats.
CAS:
251375-82-3
Molecular Weight:
451.47
Purity:
0.98
SMILES:
O=C(O)CC(O)(C(=O)O)CC(=O)O.N1=CC=C(N1C)C(OCCN(C)C)C=2C=CC=CC2
References
Costantini E, Lazzeri M. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol. 2010 Jan;57(1):152-3. doi: 10.1016/j.eururo.2009.04.046. Epub 2009 May 7. PubMed PMID: 19446952.
Soljanik I. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol. 2010 Jan;57(1):153. doi: 10.1016/j.eururo.2009.04.047. Epub 2009 May 7. PubMed PMID: 19446950.
Z?t'ura F, Vsetica J, Abad?as M, Pavl?k I, Schraml P, Brod'?k M, Villoria J, Sust M; E-4018/CL50 Study Group. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol. 2010 Jan;57(1):145-52. doi: 10.1016/j.eururo.2009.04.045. Epub 2009 May 7. PubMed PMID: 19446951.
Mart?nez-Garc?a R, Abad?as M, Ara?? P, Perales L, Ru?z JL, Sust M, Conejero J; ESCLIN 006/00 study group. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. Eur Urol. 2009 Jul;56(1):184-90. doi: 10.1016/j.eururo.2008.04.027. Epub 2008 Apr 18. PubMed PMID: 18485575.